CLINICAL CANCER THERAPY RESEARCH NIH GUIDE, Volume 21, Number 15, April 17, 1992 PA NUMBER: PA-92-69 P.T. 34 Keywords: Cancer/Carcinogenesis Clinical Medicine, General Chemotherapy Treatment, Medical+ Drug Metabolism Pharmacology National Cancer Institute PURPOSE The National Cancer Institute (NCI) seeks grant applications to conduct clinical therapeutic studies of neoplastic diseases in humans. Clinical research, by definition, involves a clinician/patient-subject interaction with a therapeutic intent. This Program Announcement (PA) encompasses a full range of therapeutic studies and clinical trials employing drugs, biologics, radiation, and surgery. The intent of the announcement is to encourage clinical researchers to translate insights in cancer biology and the development of new agents into innovative cancer therapeutic studies. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Clinical Cancer Therapy Research, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments and eligible agencies of the Federal government. Foreign institutions are not eligible for the First Independent Research Support and Transition (FIRST) Award (R29). Applications from minority individuals and women are encouraged. An application may include one or more institutions (e.g., individual institutions, consortia, cancer centers) with established clinical, laboratory, and statistical resources. MECHANISM OF SUPPORT Awards will be made as investigator-initiated research grants (R29, R01 and interactive R01s) through the National Institutes of Health (NIH) grant-in-aid, in accordance with PHS policies applicable to research project grants. This latter mechanism is used when the NCI wishes to stimulate investigator-initiated research projects in areas of special interest to the National Cancer Program. A description of an interactive R01 application can be found in the NIH Guide for Grants and Contracts (Vol. 21, No. 1, January 10, 1992) under PA-92-29. The special eligibility criteria for the FIRST Award (R29) can be found in the Guidelines for FIRST AWARD (version February 1991), which may be obtained from the Grants Inquiries Office, Division of Research Grants, NIH. Responsibility for the planning, direction, and execution of the proposed research will be solely that of the applicant. Awards will be administered under PHS grants policy as stated in the Public Health Service Grants Policy Statement, DHHS Publication No. (OASH) 82-50,000, revised January 1, 1987. RESEARCH OBJECTIVES Summary In the past several years, the research effort into understanding the basic biology of the cancer cell has been highly productive. Recent discoveries concerning the role of growth factors, genes that promote and suppress neoplasia, mechanisms of treatment sensitivity and resistance, and the biology of the immune systems have provided the basis for the development of novel and improved cancer treatments. The rate of progress in the treatment of cancer will depend upon the translation of these basic and preclinical discoveries into clinical cancer therapies. The NCI supports an extensive network of clinical and laboratory research studies related to cancer therapy through contracts, grants, and cooperative agreements. At present, the traditional research grant mechanism (R01, R29) is underutilized by clinical investigators for the support of clinical research. The Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment, NCI, the program primarily responsible for the promotion and translation of new basic and preclinical research into therapeutic advances, receives relatively few research grant applications. Whereas a Request for Applications (RFA) represents a single solicitation, a PA provides the opportunity for the receipt of new applications on a continuing basis. NCI encourages clinical investigators to submit clinical therapeutic studies and is committed to moving advances in basic biology and drug development into the clinical setting. Clinical studies must involve human subjects and be designed to ultimately improve cancer treatment. The applications may include single or multi-institutional research studies with appropriate biological correlates linked to these studies. New clinical therapeutic studies may employ drugs, biologics, radiation, or surgery used as single agents/modalities or in combination. Biological correlative studies that have clinical relevance to cancer therapies and are aimed at improving cancer treatment are also appropriate. Some examples of clinical therapeutic studies include: (1) therapies based on novel mechanisms of action, mechanism of action and metabolic studies of antitumor agents; (2) studies of mechanisms of hormone-, drug-, or radiation-resistance and reversal; (3) mechanism of action of biological response modifiers in the treatment of cancer, e.g., cancer immunotherapy (monoclonal antibodies, cytokines, antisense, and vaccines) alone or in combination with chemotherapeutic agents; (4) mechanism of action of new growth factor targeted therapies; (5) new radiation therapies or radiation modifiers to enhance cell kill or protect normal tissue; (6) surgical therapies in combination with therapeutic agents. Some examples of biological correlative studies include: (1) phenotypic or genotypic alterations that appear to correlate with the development of drug-, hormone-, or radiation-resistance; (2) oncogenes, growth factors, and specific antigen expression on tumor cells; (3) pharmacokinetic and pharmacodynamic measurements; (4) biochemical pharmacologic parameters; (5) imaging studies to assess efficacy of treatment. Investigators are not limited to the above areas of potential studies. Clinical research, by definition, must involve a clinician/patient-subject interaction with a therapeutic intent. Objectives The aims of this initiative are two-fold: (1) to support innovative correlative laboratory studies relevant to therapeutic clinical trials and (2) to stimulate development of innovative therapeutic clinical studies with laboratory correlations to foster the development of interactions between basic science laboratories and clinicians performing these clinical trials. STUDY POPULATION SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF FEMALES AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical research grants and cooperative agreements will be required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale should be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information should be included in the form PHS 398 in Section 2, 1-4 of the Research Plan AND summarized in Section 2, E, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans (including American Indians or Alaskan Natives), Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research is defined as human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities. If the required information is not contained within the application, the application will be deferred until the information is provided. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91) and will be accepted at the deadlines indicated in the application kit (February 1, June 1, and October 1). Specific application procedures for interactive R01 applications can be found in the NIH Guide for Grants and Contracts (Vol. 21, No. 1 - January 10, 1992) under PA-92-29. Application kits are available at most institutional business offices and may be obtained from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301/496-7441. The title and number of the announcement must be typed in Section 2a on the face page of the application. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources are requested to identify the GCRC as a source for conducting the proposed research. In such a case, a letter of agreement from either the GCRC program director or Principal Investigator must be included with the application. The completed original application and five legible copies must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892 ** REVIEW PROCEDURES Applications will be assigned on the basis of established Public Health Service referral guidelines. Applications will be reviewed for scientific and technical merit by study sections of the Division of Research Grants, NIH, in accordance with the standard NIH peer review procedures. Following scientific-technical review, the applications recommended for further consideration will receive a second-level review by the appropriate national advisory council. AWARD CRITERIA Applications will compete for available funds with all other approved applications. The following will be considered in making funding decisions: o Quality of the proposed project as determined by peer review o Availability of funds o Program balance among research areas of the announcement INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Dr. Roy S. Wu or Ms. Diane Bronzert NCI Program Directors Cancer Therapy Evaluation Program Division of Cancer Treatment National Cancer Institute Executive Plaza North, Room 734 Bethesda, MD 20892 Telephone: (301) 496-8866 FAX: (301) 480-4663 Direct inquiries regarding fiscal matters to: Ms. Marian Focke Grants Management Specialist National Cancer Institute Executive Plaza South, Room 242 Bethesda, MD 20892 Telephone: (301) 496-7800, ext. 46 FAX: (301) 496-8601 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No 93.395, Cancer Treatment Research. Awards are made under the authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations at 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |